Mammary Cell News Volume 14.40 | Oct 27 2022

    By
    Laurisa Dohm
    -
    0
    47








    2022-10-27 | MCN 14.40


    Mammary Cell News by STEMCELL Technologies
    Vol. 14.40 – 27 October, 2022
    TOP STORY

    Ferroptosis Heterogeneity in Triple-Negative Breast Cancer Reveals an Innovative Immunotherapy Combination Strategy

    Investigators discovered that TNBCs had heterogeneous phenotypes in ferroptosis-related metabolites and metabolic pathways.
    [Cell Metabolism]

    AbstractFull ArticleGraphical Abstract
    Explore Antibodies for Epithelial Cell Markers
    PUBLICATIONSRanked by the impact factor of the journal

    MYO10-Filopodia Support Basement Membranes at Pre-invasive Tumor Boundaries

    Myosin-X (MYO10) promoted filopodia formation and cell invasion in vitro, and cancer-cell dissemination from progressively invasive human ductal carcinoma in situ xenografts.
    [Developmental Cell]

    AbstractFull ArticleGraphical Abstract

    STAT5 Confers Lactogenic Properties in Breast Tumorigenesis and Restricts Metastatic Potential

    Investigators showed that STAT5aca reduced the migratory and invasive ability of human breast cancer cell lines in vitro. They demonstrated that STAT5aca overexpression in human breast cancer cells lowered their metastatic burden in xenografted mice.
    [Oncogene]

    Full Article

    Integrin Regulation by Tissue Factor Promotes Cancer Stemness and Metastatic Dissemination in Breast Cancer

    Tissue factor blockade caused a reduction in epithelial-to-mesenchymal-transition, cancer stemness, and expression of the pro-metastatic markers Slug and SOX9 in several breast cancer cell lines and in ex vivo cultured tumor cells.
    [Oncogene]

    Abstract

    Development and Characterisation of 3D Collagen-Gelatin Based Scaffolds for Breast Cancer Research

    Scaffolds displayed high in vitro stability with 90% of mass remaining after 14 days of culture. They were also highly biocompatible, and capable of supporting the attachment, infiltration and proliferation of MCF7 breast cancer cells.
    [Biomaterials Advances]

    AbstractGraphical Abstract

    RBCK1 Is an Endogenous Inhibitor for Triple Negative Breast Cancer via Hippo/YAP Axis

    RBCK1 over-expression inhibited TNBC cell progression in vitro and in vivo, while RBCK1 depletion promoted TNBC cell invasion.
    [Cell Communication and Signaling]

    Full Article

    Long Non-Coding RNA HOTAIR Regulates the Stemness of Breast Cancer Cells via Activation of the NF-κB Signaling Pathway

    Scientists found that the long noncoding RNA HOTAIR is highly expressed in breast cancer stem cells (CSCs). HOTAIR was required for breast CSC self-renewal and tumor propagation.
    [Journal of Biological Chemistry]

    Full Article
    View tips on how to share lab duties effectively.
    REVIEWS

    Systemic Therapy for Early-Stage Breast Cancer: Learning from the Past to Build the Future

    The authors summarize the evolution of (neo)adjuvant trials from the pre-genomic to the post-genomic era and provide critical insights into how neoadjuvant studies are currently designed, discussing the need for better end points.
    [Nature Reviews Clinical Oncology]

    Abstract

    3D Bioprinted Cancer Models: From Basic Biology to Drug Development

    Scientists present the state of the art of 3D bioprinted cancer modelling, focusing on the biological processes that underlie the molecular mechanisms involved in cancer progression and treatment response as well as on proteomic and genomic signatures.
    [Nature Reviews Cancer]

    Abstract
    INDUSTRY AND POLICY NEWS

    BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

    BriaCell Therapeutics Corp. announced the completion of the Phase I part of the clinical trial of its lead candidate, Bria-IMT™, in combination with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer.
    [BriaCell Therapeutics Corp.]

    Press Release
    FEATURED EVENT

    Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy

    January 29 – February 2, 2023
    Banff, Alberta, Canada

    > See All Events

    JOB OPPORTUNITIES

    Medical Science Liaison – Breast Cancer

    AstraZeneca – Mississauga, Ontario, Canada

    Postdoctoral Position – Advanced Tumoroid Biology

    Ludwig Maximilians University of Munich – Munich, Germany

    Associate/Senior Editor – Molecular Biology, Genetics

    Nature Communications – London, Berlin, New York, Shanghai (Hybrid)

    Clinical Director – Department of Health and Human Services

    NCI – Bethesda, Maryland, United States

    Postdoctoral Researcher – Molecular Biology

    Italian Institute of Technology – Genoa, Italy

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter